Efficacy and safety in real clinical conditions of Raltegravir in a reference hospital of peruvian social security
Abstract
Introduction: Rategravir belongs to integrase inhibitors, being demonstrated and approved by several clinical trials as a powerful and safe antiretroviral drug for the treatment of patients infected with human immunodeficiency virus (HIV), with good tolerance and low toxicity, including in the third line or rescue scheme and it starts when the first and second lineas schemes have failed.
Objective: To evaluate the efficacy and safety in real clinical conditions of the use of Raltegravir within the HAART schemes in patients with HIV infection in a reference hospital of social insurance in Peru.
Methods: A retrospective observational study was performed in patients with a diagnosis of HIV infection who started treatment within the TARGA scheme based on Raltegravir with follow-up and control at 6 months. We presented summary measures of frequencies and percentages for the qualitative variables, as well as means and standard deviation for the quantitative variables based on the results of the normality tests. The data was processed and analyzed in the statistical software SPSS version 22.
Results: The male gender was the most affected with 76% (n = 119) of the total. The most frequent age range was between 45 to 55 years (25.4%, n = 40). The most frequent comorbidities were Diabetes mellitus and arterial hypertension, with exponential reduction in viral load and elevation of CD4 lymphocyte levels.
Conclusion: Raltegravir is effective for the treatment of HIV patients.
Downloads
References
Mouscadet J-F, Tchertanov L. Raltegravir: molecular basis of its mechanism of action. Eur J Med Res. 2009;14(Suppl 3):5-16.
Gatell JM. Eficacia del raltegravir: desde los voluntarios sanos a la fase III. Enfermedades Infecc Microbiol Clínica. 2008;26:29-33.
Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F, et al. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study. AIDS Res Hum Retroviruses. 2013;29(6):859-70.
Funderburg NT, Xu D, Playford MP, Joshi AA, Andrade A, Kuritzkes DR, et al. Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. Antivir Ther. 2017;22(1):71-5.
DIGEMID. Informe Técnico N°09-2011. Raltegravir. 2011. Report No.: 9.
Gantner P, Koeppel C, Partisani M, Batard M-L, Bernard-Henry C, Cheneau C, et al. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. Scand J Infect Dis. 2014;46(12):838-45.
Mata-Marín JA, Smeke AEW, Rodriguez MR, Chávez-García M, Banda-Lara MI, Rios AMP, et al. Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients. Drugs RD. 2017;17(1):225-31.
Jaeckle M, Khaykin P, Haberl A, De Leuw P, Schüttfort G, Stephan C, et al. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice. Int J STD AIDS. 2016;27(13):1170-9.
O Malpartida GP-L, J Collins, JL Magallanes, PA Castro, RA Castillo, JA Hidalgo, et al. Real‐life use of raltegravir: experience from Hospital Guillermo Almenara, Essalud, Lima, Peru. Speaker Abstracts presentado en: HIV & Hepatitis in the Americas 19–21 April 2018; 2018; Mexico.
Pavone P, Giustini N, Fimiani C, Paoletti F, Falciano M, Salotti A, et al. Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age Study. Curr HIV Res. 2017;15(5):355-60.
The works published in this magazine are subject to the following terms:
1. The Publications Service of the University of Murcia (the publisher) preserves the copyright of the published works, and encourages and allows the reuse of the works under the license for use stated in point 2.
© Servicio de Publicaciones, Universidad de Murcia, 2011 (© Publications Service, University of Murcia, 2011)
2. The works are published in the electronic edition of the journal under Creative Commons Reconocimiento-NoComercial-SinObraDerivada 3.0 España(texto legal) “ a Attribution-NonCommercial-NoDerivatives 3.0 Spain license (legal text)”. They can be copied, used, broadcasted, transmitted and publicly displayed, provided that: i) the authorship and original source of their publication (journal, publisher and URL) are cited; (ii) are not used for commercial purposes; iii) the existence and specifications of this license is mentioned.
3. Conditions of self-archiving. Authors are allowed and encouraged to electronically disseminate the pre-print (pre-reviewed ) and / or post-print (reviewed and accepted for publication) versions of their works prior to publication, as it ensures a wider circulation and dissemination which may lead to a possible increase in its mention and a higher scope among the academic community. RoMEO color: green.
